首页> 外文期刊>BMC Complementary and Alternative Medicine >The risk of coronary artery disease in patients with rheumatoid arthritis using Chinese herbal products and conventional medicine in parallel: a population-based cohort study
【24h】

The risk of coronary artery disease in patients with rheumatoid arthritis using Chinese herbal products and conventional medicine in parallel: a population-based cohort study

机译:用中草药和常规医学并行使用中风关节炎患者冠状动脉疾病的风险:基于人群的队列研究

获取原文
获取外文期刊封面目录资料

摘要

Few studies have evaluated the association between the risk of coronary artery disease (CAD) and the use of Chinese herbal products (CHP) in patients with rheumatoid arthritis (RA). This study investigated the risk of CAD among patients with RA using CHP in combination with conventional medicine. A retrospective cohort study was conducted using the Taiwan National Insurance Research Database to assess 22,353 patients who had been newly diagnosed with RA between 1997 and 2010. Patients were assigned to the CHP group or non-CHP group according to their use or nonuse of CHP after being diagnosed with RA. The Cox proportional hazards model was used to estimate the hazard ratio (HR) of CAD for a 1:1 matched sample. Both the CHP and non-CHP groups comprised 4889 patients after 1:1 matching. The risk of CAD was significantly reduced in the CHP group [adjusted HR (aHR): 0.59, 95% confidence interval (CI): 0.50–0.71] compard with the non-CHP group. Those who used CHP for ?180?days had an even lower risk of CAD than users with CHP usage less than 30?days (aHR: 0.64, 95% CI: 0.43–0.95). Additionally, frequently prescribed formulae, such as Kuei-Chih-Shao-Yao-Chih-Mu-Tang, Tang-Kuei-Nien-Tung-Tang, and Shu-Ching-Huo-Hsieh-Tang, were associated with a reduced risk of CAD. The use of CHP was associated with a lower risk of CAD in patients with RA. Additional randomized controlled trials are required to assess any causal relationship between the effect of CHP usage and the risk of CAD.
机译:很少有研究评估了冠状动脉疾病(CAD)风险与类风湿性关节炎患者(RA)的患者使用中草药(CHP)之间的关联。本研究研究了使用CHP与常规药物联合使用CHP患者CAD的风险。使用台湾国民保险研究数据库进行了回顾性队列研究,以评估1997年至2010年间新诊断的ra患者的22,353名患者。根据他们的使用或非杂志分配给CHP组或非CHP组被诊断为RA。 Cox比例危害模型用于估计1:1匹配样品的CAD的危险比(HR)。 CHP和非CHP组均在1:1匹配后组成4889名患者。 CHP组中CAD的风险显着降低[调整后的HR(AHR):0.59,95%置信区间(CI):0.50-0.71]与非CHP组载入。使用CHP的人>?180?天的CAD的风险甚至比使用CHP使用量的CAD少于30?天(AHR:0.64,95%CI:0.43-0.95)。此外,经常规定的公式,如Kuei-Chih-Shao-yao-Chih-Mu-Tang,Tang-Kuei-Nien-Tung-Tang和Shu-Ching-Huo-Hsieh-jang与降低风险有关CAD。使用CHP的使用与RA患者的CAD风险较低。需要额外的随机对照试验来评估CHP使用效果与CAD风险之间的任何因果关系。

著录项

获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号